Nasal administration

Nasus Pharma Announces Publication Of Its Positive Clinical Results With FMXIN002 Intranasal Powder Epinephrine Spray In The Journal Of Allergy And Clinical Immunology In Practice

Retrieved on: 
Tuesday, August 8, 2023
Allergen, Volunteering, PK, Injection, Tmax, Food, Allergy, PBI, Emergency, Biting, Pharmacokinetics, IM, Cmax, Parent, Trial of the century, Nose, Plasma, TEL, Anaphylaxis, AUC, Nasal congestion, Powder, Nasal administration, Death, Fatality, Pharmaceutical industry, Nasus, Adrenaline, Mylan

TEL AVIV, Israel, Aug. 8, 2023 /PRNewswire/ -- Nasus Pharma Ltd a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based Intranasal (PBI) product portfolio, to address acute medical conditions announced the publication of positive results from a clinical study of intranasal powder-based Epinephrine.

Key Points: 
  • FMXIN002 is an investigational intranasal epinephrine powder spray device that is noninvasive, user-friendly and reliable and could provide timely effective rescue for severe potentially life-threatening allergic reactions to food, medications and insect bites.
  • The clinical study provides additional compelling evidence to the robustness of Nasus Pharma's intranasal powder technology already tested in other drugs.
  • "The publication of our results in a prominent scientific journal such as JACI: In Practice will ensure the dissemination of FMXIN002's promise within the relevant medical community."
  • Yet an additional advantage for powder-based formulation of epinephrine, a drug that undergoes rapid degradation in the currently-available short shelf-life liquid dosage forms.

Global Allergic Rhinitis Drugs Market Analysis 2023-2028 by Class of Drugs, Route of Administration, Application, and Competitive Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, July 31, 2023
Health, Chemicals, Plastics, Other Consumer, Consumer, Manufacturing, Other Health, Pharmaceutical, Online, Drug, Intraocular hemorrhage, Laboratory, Recession, Ansoff matrix, Route of administration, COVID-19, Merck Group, Analysis, USD, AstraZeneca, Hospital pharmacy, Administration, Investment, Porter's five forces analysis, Geography, Online pharmacy, Observation, Nasal administration, Antihistamine, Dietary supplement, Retail, Pharmaceutical industry, Application

The "Global Allergic Rhinitis Drugs Market (2023-2028) by Class of Drugs, Route of Administration, Application, and Geography, Competitive Analysis, Impact of Economic Slowdown & Impending Recession with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Allergic Rhinitis Drugs Market (2023-2028) by Class of Drugs, Route of Administration, Application, and Geography, Competitive Analysis, Impact of Economic Slowdown & Impending Recession with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Global Allergic Rhinitis Drugs Market is estimated to be USD 12.06 Bn in 2023 and is expected to reach USD 15.41 Bn by 2028, growing at a CAGR of 5.03%.
  • The report offers a comprehensive evaluation of the Global Allergic Rhinitis Drugs Market.
  • The report includes an in-depth Market analysis using Porter's 5 forces model, PESTLE Analysis, and the Ansoff Matrix.

Regeneration and Reinnervation of Spinal Cord in Rats Treated with NurExone's Intranasal ExoPTEN

Retrieved on: 
Thursday, June 22, 2023
Rat, Magnetic resonance imaging, DTI, Tetraplegia, Spinal cord, Survival, Diffusion MRI, FSE, Research, NRX, TEL, Reinnervation, MRI, Regeneration, Animal, Patient, Neuroregeneration, Nasal administration, Exosome, FA, SCI, Trauma, Trapping, Medical imaging

The image analysis and measurements confirmed successful nerve regeneration following traumatic transection of the spinal cord in rats.

Key Points: 
  • The image analysis and measurements confirmed successful nerve regeneration following traumatic transection of the spinal cord in rats.
  • Subsequently, the spinal cords of rats from the study were subjected to advanced Diffusion Tensor Imaging (DTI) to assess the structural integrity of the spinal cord.
  • ExoPTEN is being developed to be a minimally invasive ExoTherapy for spinal cord injuries (SCI) administrated intranasally and yielding neuron regeneration and rewiring in traumatically damaged spinal cords.
  • These DTI tractography images and measurements indicate re-innervation and nourishment to the caudal spinal cords in ExoPTEN rats treated intranasally.

ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

Retrieved on: 
Tuesday, June 20, 2023
Prescription Drug User Fee Act, Allergy, ARS, Anxiety, European Medicines Agency, New Drug Application, Adrenaline, NDA, Patient, Anaphylaxis, SAN, PDUFA, Nasal administration, Entrepreneurship, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Caregiver, Pharmaceutical industry, Agency

SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc .

Key Points: 
  • SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc .
  • The updated PDUFA target action date is September 19, 2023.
  • The additional time is needed for labeling and post-marketing commitment discussions regarding neffy, and ARS has submitted proposals for post-marketing commitments based on input from the PADAC meeting in May.
  • “FDA is working on labeling and post-marketing commitments as the final steps in the review process,” said Richard Lowenthal, Co-Founder, President and Chief Executive Officer, ARS Pharmaceuticals.

ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer’s Disease

Retrieved on: 
Thursday, April 13, 2023
ASC, Central nervous system, University, Disability, Albert Einstein's brain, Ageing, Deficit spending, NLRP3, DRS, Research, MCI, Frontiers Media, Administration, Dysfunction, Invention, Microglia, Nasal administration, AD, Therapy, Death, Encephalitis, Spatial memory, Pharmaceutical industry, Vaccine, Pharmacology

In the paper titled, “Microglia: A pharmacological target for the treatment of age-related cognitive decline and Alzheimer’s disease,” the authors reviewed data associated with microglial pathways that have potential as drug targets for treatment of MCI and AD.

Key Points: 
  • In the paper titled, “Microglia: A pharmacological target for the treatment of age-related cognitive decline and Alzheimer’s disease,” the authors reviewed data associated with microglial pathways that have potential as drug targets for treatment of MCI and AD.
  • “It is encouraging to see the extensive research underway to identify potential drug targets.
  • We are proud of the original scientific contributions in this area by the inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100, Drs.
  • Robert W. Keane and Juan Pablo de Rivero Vaccari at the University of Miami Miller School of Medicine.” To review their latest publication on Alzheimer’s disease, Click Here .

Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage

Retrieved on: 
Tuesday, April 4, 2023
Intracerebral hemorrhage, Nasal administration, Stroke, Patient, Speech, Pharmaceutical industry

Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemorrhagic stroke

Key Points: 
  • Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemorrhagic stroke
    NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody in a model of intracerebral hemorrhage (hemorrhagic stroke) demonstrating a behavioral outcome improvement at one month.
  • Intranasal anti-CD3 monoclonal antibody showed improved motor and cognitive outcomes at one-month post-intracerebral hemorrhage which is very exciting,” commented Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana.
  • “We are actively exploring the clinical development pathway in intracerebral hemorrhage using intranasal foralumab, the first-ever fully human anti-CD3 monoclonal antibody in patients suffering from a hemorrhagic stroke.
  • This new exciting finding further validates our decision to focus on the clinical development of our lead asset, intranasal foralumab.

InvisiShield Technologies Collaborates with Gladstone Institutes to Accelerate Development of Intranasal Preventatives against SARS-CoV-2, Influenza, and RSV

Retrieved on: 
Monday, March 20, 2023
Health, Medical Devices, Infectious Diseases, COVID-19, General Health, Pharmaceutical, Biotechnology, HIV/AIDS, Vaccination, SARS-CoV-2, Infection, Biosafety, Viral, Respiratory syncytial virus, Nose, RSV, Gladstone Institutes, Nasal administration, Safety, Vaccine, Virology, William Ewart Gladstone

InvisiShield Technologies Ltd., a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses, today announced a collaboration with Gladstone Institutes to develop intranasal preventatives against airborne infection, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV).

Key Points: 
  • InvisiShield Technologies Ltd., a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses, today announced a collaboration with Gladstone Institutes to develop intranasal preventatives against airborne infection, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV).
  • Gladstone has made significant contributions to better understanding and developing new therapies for a range of viral diseases, including HIV/AIDS and COVID-19.
  • The collaboration aims to develop intranasal preventatives that can protect individuals from viral infections, including SARS-CoV-2, the virus that causes COVID-19, as well as influenza and RSV.
  • InvisiShield Technologies and Gladstone are committed to advancing medical research and addressing unmet medical needs.

Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 8, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Offering, G&A, Canada, Acquisition, Growth, USD, NDA, PP, Cognition, CAD, FDA, TBI, Nasal administration, R, AD, ACOG, Research, Depreciation, Marketing, Pharmaceutical industry, Security (finance), Cryptocurrency

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.
  • Additionally, the Company continues to manage its cash judiciously to extend runway while continuing to explore partnerships and other opportunities."
  • In addition, the amendment now incorporates both Alpha Cognition Inc. and Alpha Cognition Canada Inc. under the Memogain Technology Agreement and added clarity to certain terms and definitions under the license agreement.
  • Cash and cash equivalents at December 31, 2022 were $2.1 million.

World Alzheimer's Disease Therapeutics Analysis Report 2022: 101 Active Drugs - Market Insight, Epidemiology and Pipeline Assessment by Molecule Type, Route of Administration, Pipeline Phase - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Health, Pharmaceutical, Molecule, Administration, Food, Therapy, MEA, Research, Intrathecal administration, Nasal administration, Disease, Nature, Novartis, Science, Life expectancy, Diagnosis, Eisai, Biogen, FDA, Intramuscular injection, Cognition, Route of administration, Food and Drug Administration Amendments Act of 2007, A/S, Athira Pharma, Epidemiology, Intravenous therapy, Prevalence, Monoclonal antibody, Oral, Medicinal plants, Pharmaceutical industry, Alzheimer's disease

The "Alzheimer's Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alzheimer's Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)" report has been added to ResearchAndMarkets.com's offering.
  • Alzheimer's disease Therapeutics Pipeline Analysis has 101 active drugs undergoing several stages of clinical trials.
  • The Alzheimer's disease Therapeutics Pipeline is driven by an increasing gap of unmet need of effective therapeutics that can cure Alzheimer's disease.
  • The report analyses the Alzheimer's disease Therapeutics by Pipeline Phase (Phase I, Phase I/II, Phase II, Phase II/III, Phase III, Phase IV, Preclinical).

mRNA Therapeutics and mRNA Vaccines Market by Route of Administration, Therapeutic Area, and Geography : Global Trends and Industry Analysis, 2022-2035

Retrieved on: 
Friday, November 18, 2022
Intravenous therapy, Growth, RNA transfection, CureVac, RNA, Route of administration, III, Ribosome, EUA, Therapy, Disorder, Infection, Partnership, CPC, Vaccine, R, Pfizer–BioNTech COVID-19 vaccine, GMP, Half-life, Intramuscular injection, Research, Initial public offering, Investment, Administration, DNA, Q5, COVID-19, Degenerative disease, Toxicity, Risk, BioNTech, Liposome, Clinical trial, Nasal administration, Protein, Disease, Pharmaceutical industry, Aquaculture, Messenger, Geography, USD, Pfizer

In addition, over 1,000 mRNA therapeutics are being evaluated in various stages of clinical trials for the treatment of multitude of disease indications.

Key Points: 
  • In addition, over 1,000 mRNA therapeutics are being evaluated in various stages of clinical trials for the treatment of multitude of disease indications.
  • What are the current opportunities in the mRNA therapeutics and vaccines market?
  • In the past few years, the field of mRNA therapeutics and vaccines has evolved at a steady pace.
  • What are the recent developments and expected trends in the mRNA therapeutics and vaccines industry?